viewThe Conscious Fund

The Conscious Fund seizing early-stage opportunities in psychedelic medicines

The Conscious Fund's Henri Sant-Cassia tells Proactive London's Andrew Scott they're looking at plant-based medicines with the current focus being on psychedelic medicines - including drug discovery plays and clinic plays around mental health and addiction.

''Typically we're talking psychedelic compounds like magic mushrooms, ketamine and MDMA'', he says.

''Broadly these are all compounds which are now being used for mental health, addiction treatment and also mental wellbeing''.

''There's such interest in plant based medicines currently that the FDA have granted certain drugs breakthrough therapy status ... these are substances with such potential to change the mental health landscape that they are fast-tracking them through the normal regulatory approval process''.

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...


Metal Tiger on Kitlanya East copper-silver project progress and oncoming...

Metal Tiger PLC's (LON:MTR) Michael McNeilly catches up with Proactive London's Katie Pilbeam after reporting progress at the Kitlanya East copper-silver project in Botswana, operated by Kalahari Metals Ltd (KML). McNeilly explains the potential for the South Fold target to host copper-silver...

7 hours, 19 minutes ago

2 min read